DelveInsight's"Chronic Idiopathic Urticaria Market Insights, Epidemiology, and Market Forecast-2032"report delivers an in-depth understanding of the Chronic Idiopathic Urticaria, historical and forecasted epidemiology as well as the Chronic Idiopathic Urticaria market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Chronic Idiopathic Urticaria market report provides current treatment practices, emerging drugs, Chronic Idiopathic Urticaria market share of the individual therapies, current and forecasted Chronic Idiopathic Urticaria market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Chronic Idiopathic Urticaria treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of theChronic Idiopathic Urticaria market.
Geography Covered
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
- Japan
Study Period: 2019-2032
Chronic Idiopathic Urticaria Disease Understanding and Treatment Algorithm
TheDelveInsight’sChronic Idiopathic Urticaria market report gives a thorough understanding of the Chronic Idiopathic Urticaria by including details such as disease definition, symptoms, causes, pathophysiology, diagnosis, and treatment.
Chronic Idiopathic Urticaria Diagnosis
This segment of the report covers the detailed diagnostic methods or tests for Chronic Idiopathic Urticaria.
Chronic Idiopathic Urticaria Treatment
It covers the details of conventional and current medical therapies available in the Chronic Idiopathic Urticaria market for the treatment of the condition. It also provides Chronic Idiopathic Urticaria treatment algorithms and guidelines in the United States, Europe, and Japan.
Chronic Idiopathic Urticaria Epidemiology
The Chronic Idiopathic Urticaria epidemiologysectionprovides insights about the historical and current Chronic Idiopathic Urticaria patient pool and forecasted trends forindividualseven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of theChronic Idiopathic Urticaria market report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
Key Findings
The disease epidemiology covered in the report provides historical as well as forecasted Chronic Idiopathic Urticaria epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Chronic Idiopathic Urticaria Epidemiology
The epidemiology segment also provides the Chronic Idiopathic Urticaria epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
Chronic Idiopathic Urticaria Drug Chapters
The drug chapter segment of the Chronic Idiopathic Urticaria report encloses the detailed analysis of Chronic Idiopathic Urticaria marketed drugs and late-stage (Phase-III and Phase-II)Chronic Idiopathic Urticaria pipeline drugs. It also helps to understand the Chronic Idiopathic Urticaria clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases.
Chronic Idiopathic Urticaria Marketed Drugs
The report provides the details of the marketed products/off-label treatments available for Chronic Idiopathic Urticaria treatment.
Chronic Idiopathic Urticaria Emerging Drugs
The report provides the details of the emerging therapies under the late and mid-stage of development for Chronic Idiopathic Urticaria treatment.
Chronic Idiopathic Urticaria Market Outlook
The Chronic Idiopathic Urticaria market outlook of the report helps to build a detailed comprehension of the historic, current, and forecasted Chronic Idiopathic Urticaria market trends by analyzing the impact of currentChronic Idiopathic Urticaria therapies on the market, unmet needs, drivers and barriers, and demand for better technology.
This segment gives a thorough detail of Chronic Idiopathic Urticaria market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Chronic Idiopathic Urticaria market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
According to DelveInsight, the Chronic Idiopathic Urticaria market in 7MM is expected to witness a major change in the study period 2019-2032.
Key Findings
This section includes a glimpse of the Chronic Idiopathic Urticaria market in 7MM.
The United States Chronic Idiopathic Urticaria Market Outlook
This section provides the total Chronic Idiopathic Urticaria market size and market size by therapies in the United States.
EU-5 Countries: Chronic Idiopathic Urticaria Market Outlook
The total Chronic Idiopathic Urticaria market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom is provided in this section.
Japan Chronic Idiopathic Urticaria Market Outlook
The total Chronic Idiopathic Urticaria market size and market size by therapies in Japan is also mentioned.
Chronic Idiopathic Urticaria Drugs Uptake
This section focuses on the rate of uptake of the potential Chronic Idiopathic Urticaria drugsrecently launched in the Chronic Idiopathic Urticaria market or expected to get launched in the market during the study period 2019-2032. The analysis covers Chronic Idiopathic Urticaria market uptake by drugs; patient uptake by therapies; and sales of each drug.
Chronic Idiopathic Urticaria Drugs Uptake helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs, and allow the comparison of the drugs on the basis of Chronic Idiopathic Urticaria market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.
Chronic Idiopathic Urticaria Pipeline Development Activities
TheChronic Idiopathic Urticaria report provides insights into different therapeutic candidates in Phase II, and Phase III stage. It also analyses Chronic Idiopathic Urticaria key players involved in developing targeted therapeutics.
Pipeline Development Activities
The Chronic Idiopathic Urticaria report covers the detailed information of collaborations, acquisition, and merger, licensing, patent details, and other information for Chronic Idiopathic Urticaria emerging therapies.
Reimbursement Scenario in Chronic Idiopathic Urticaria
Approaching reimbursement proactively can have a positive impact both during the late stages of product development and well after product launch. In a report, we take reimbursement into consideration to identify economically attractive indications and market opportunities. When working with finite resources, the ability to select the markets with the fewest reimbursement barriers can be a critical business and price strategy.
KOL- Views
To keep up with current Chronic Idiopathic Urticaria market trends, we take KOLs and SMEs ' opinion working in the Chronic Idiopathic Urticaria domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate current and emerging therapies treatment patterns or Chronic Idiopathic Urticaria market trends. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the market and the unmet needs.
Competitive Intelligence Analysis
We perform Competitiveand Market Intelligence analysis of the Chronic Idiopathic Urticaria Market by using various Competitive Intelligence tools that include -SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategiesetc. The inclusion of the analysis entirely depends upon the data availability.
Scope of the Report
- The report covers the descriptive overview of Chronic Idiopathic Urticaria, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
- Comprehensive insight has been provided into the Chronic Idiopathic Urticaria epidemiology and treatment in the 7MM
- Additionally, an all-inclusive account of both the current and emerging therapies for Chronic Idiopathic Urticaria is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
- A detailed review of the Chronic Idiopathic Urticaria market; historical and forecasted is included in the report, covering drug outreach in the 7MM
- The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Chronic Idiopathic Urticaria market
Report Highlights
- In the coming years, the Chronic Idiopathic Urticaria market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Idiopathic Urticaria R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Chronic Idiopathic Urticaria. The launch of emerging therapies will significantly impact the Chronic Idiopathic Urticaria market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Chronic Idiopathic Urticaria
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Chronic Idiopathic Urticaria Report Insights
- Chronic Idiopathic Urticaria Patient Population
- Therapeutic Approaches
- Chronic Idiopathic Urticaria Pipeline Analysis
- Chronic Idiopathic Urticaria Market Size and Trends
- Chronic Idiopathic Urticaria Market Opportunities
- Impact of upcomingChronic Idiopathic Urticaria Therapies
Chronic Idiopathic Urticaria Report Key Strengths
- 11Years Forecast
- 7MM Coverage
- Chronic Idiopathic Urticaria Epidemiology Segmentation
- Key Cross Competition
- Highly Analyzed Market
- Drugs Uptake
Chronic Idiopathic Urticaria Report Assessment
- Current Treatment Practices
- Unmet Needs
- Chronic Idiopathic Urticaria Pipeline Product Profiles
- Chronic Idiopathic Urticaria Market Attractiveness
- Market Drivers and Barriers
Key Questions
Market Insights:
- What was the Chronic Idiopathic Urticaria drug class share (%) distribution in 2019 and how it would look like in 2032?
- What would be the Chronic Idiopathic Urticaria total market size as well as market size by therapies across the 7MM during the forecast period (2019-2032)?
- What are the key findings pertaining to the market across 7MM and which country will have the largest Chronic Idiopathic Urticaria market size during the forecast period (2019-2032)?
- At what CAGR, the Chronic Idiopathic Urticaria market is expected to grow by 7MM during the forecast period (2019-2032)?
- What would be the Chronic Idiopathic Urticaria market outlook across the 7MM during the forecast period (2019-2032)?
- What would be the Chronic Idiopathic Urticaria market growth till 2032, and what will be the resultant market Size in the year 2032?
- How would the unmet needsaffect the market dynamics and subsequent analysis of the associated trends?
Epidemiology Insights:
- What are the disease risk, burden, and regional/ethnic differences of the Chronic Idiopathic Urticaria?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical Chronic Idiopathic Urticaria patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of Chronic Idiopathic Urticaria in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM with respect to the patient population pertaining to Chronic Idiopathic Urticaria?
- Out of all 7MM countries, which country would have the highest prevalent population of Chronic Idiopathic Urticaria during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow in7MM during the forecast period (2019-2032)?
Current Treatment Scenario, Marketed Drugs and Emerging Therapies:
- What are the current options for the Chronic Idiopathic Urticaria treatment in addition to the approved therapies?
- What are the current treatment guidelines for the treatment of Chronic Idiopathic Urticaria in the USA, Europe, and Japan?
- What are the Chronic Idiopathic Urticaria marketed drugs and their respective MOA, regulatory milestones, product development activities, advantages, disadvantages, safety and efficacy, etc.?
- How many companies are developing therapies for the treatment of Chronic Idiopathic Urticaria?
- How many therapies are in-development by each company for Chronic Idiopathic Urticaria treatment?
- How many are emerging therapies in mid-stage, and late stage of development for Chronic Idiopathic Urticaria treatment?
- What are the key collaborations (Industry - Industry, Industry - Academia), Mergers and acquisitions, licensing activities related to the Chronic Idiopathic Urticaria therapies?
- What are the recent novel therapies, targets, mechanisms of action and technologies being developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Idiopathic Urticaria and their status?
- What are the current challenges faced in drug development?
- What are the key designations that have been granted for the emerging therapies for Chronic Idiopathic Urticaria?
- What are the global historical and forecasted market of Chronic Idiopathic Urticaria?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the Chronic Idiopathic Urticaria market
- To understand the future market competition in the Chronic Idiopathic Urticaria market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for Chronic Idiopathic Urticaria in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for Chronic Idiopathic Urticaria market
- To understand the future market competition in the Chronic Idiopathic Urticaria market
Frequently Asked Questions
What is Chronic Idiopathic Urticaria?
Chronic idiopathic urticaria (CIU) is a distressing skin condition that causes red, swollen, itchy and sometimes painful hives or “wheals” on the skin. It is being associated with autoimmunity in almost half of the cases but the remaining cases still remains “idiopathic” and all are considered spontaneous.
Who are the leading companies in Chronic Idiopathic Urticaria Market Landscape?
The leading companies that are working in the Chronic Idiopathic Urticaria Market are Novartis, Genentech, Kiniksa pharmaceuticals, Sanofi, Proinnovera and others.
What are the key strengths of Chronic Idiopathic Urticaria Market Report?
Key strengths of Chronic Idiopathic Urticaria Market Report are 11 Years Forecast, 7MM Coverage, Epidemiology Segmentation, Market Size, Drug Uptake, Pipeline Therapies, Market Drivers and Market Barriers.
Which country is expected to account for the most significant prevalent cases for Chronic Idiopathic Urticaria in the 7MM?
The US is expected to account for the highest Chronic Idiopathic Urticaria prevalent cases.
FAQs
What is the market size of chronic urticaria? ›
The market size of Chronic Spontaneous Urticaria in the seven major markets was found to be USD 1,315.3 million in 2021.
What is the epidemiology of chronic urticaria? ›Chronic spontaneous (idiopathic) urticaria (CSU), defined as the occurrence of wheals, angioedema, or both for more than 6 weeks, affects 1–2% of the population.
What is the new treatment for CIU? ›Ligelizumab is a next-generation monoclonal anti-immunoglobulin E (IgE) antibody. Ligelizumab is thought to work by blocking the IgE/FcεRI pathway, a key driver of the inflammatory process in CIU6,7.
What causes chronic idiopathic urticaria? ›Chronic idiopathic urticaria isn't an allergy and isn't contagious. It's probably caused by a combination of factors. These may include environmental irritants, your immune system, and genetics. It can also be a response to a bacterial, fungal, or viral infection.
Can you get disability for chronic urticaria? ›The VA Schedule for Rating Disabilities features a listing for chronic urticaria (the medical name for chronic hives). This listing stipulates the requirements for the different levels of impairment ratings for this condition. (Your impairment rating determines how much you receive in monthly compensation.)
How rare is chronic idiopathic urticaria? ›Rarely, cases of hives last more than six weeks and can last months or up to 5 years. This condition is known as chronic spontaneous/idiopathic urticaria (ongoing, of unknown cause). It can affect 1.4% of the general population and is seen in women twice as commonly as men.
What is the best treatment for chronic urticaria? ›...
Examples include:
- Cetirizine.
- Desloratadine (Clarinex)
- Fexofenadine.
An allergist will help determine if you have acute or chronic urticaria.
Is urticaria a serious disease? ›Chronic urticaria (CU) is a disturbing allergic condition of the skin. Although frequently benign, it may sometimes be a red flag sign of a serious internal disease. A multitude of etiologies have been implicated in the causation of CU, including physical, infective, vasculitic, psychological and idiopathic.
How do people live with chronic idiopathic urticaria? ›- Use lotion. ...
- Take a cool oatmeal bath. ...
- Use cold therapy. ...
- Try a vitamin D supplement. ...
- Keep your wardrobe simple. ...
- Try an over-the-counter cream for itch relief. ...
- Resist the urge to scratch.
Which lotion is best for urticaria? ›
Topical lotions in form of calamine lotion, menthol with aqueous cream, and crotamiton lotion are useful soothing agents in the treatment.
What can trigger CIU? ›Spending time in nature is wonderful, but it can also potentially trigger your CIU. Pollen, insect bites, and the sun's heat can all lead to itchy bumps on your skin. On the other hand, the winter cold or cold conditions such as a swimming pool can also trigger a flare-up in some people.
What autoimmune diseases cause urticaria? ›...
What autoimmune diseases cause chronic hives?
- Celiac disease.
- Dermatomyositis.
- Diabetes.
- Lupus.
- Polymyositis.
- Rheumatoid arthritis.
- Thyroid disease.
- Vitiligo.
A number of foods have been reported to worsen CU symptoms. These “trigger” foods include alcohol, food additives, seafood, certain vegetables and fruits, fermented foods, and others [6].
Is idiopathic urticaria an autoimmune disease? ›It is well-recognized that 30-40% of chronic idiopathic urticaria is autoimmune in nature.
Can vitamin D help chronic urticaria? ›In addition, a randomized double-blinded controlled trial of adult patients with chronic urticaria by Rorie et al. demonstrated improved Urticaria Severity Scores following 12 week supplementation with 4000 IU of vitamin D3 per day, regardless of baseline vitamin D status [5].
Can stress and anxiety cause chronic urticaria? ›Chronic urticaria (CU) belongs to a group of psychodermatological disorders, thus stress can play a significant role in this dermatosis onset and/or exacerbation.
What other conditions are associated with chronic urticaria? ›Supporting this hypothesis, a strong association has been found between chronic urticaria and additional autoimmune diseases, such as thyroid disease, rheumatoid arthritis, systemic lupus erythematosus, Sjögren's syndrome, celiac disease and type 1 diabetes, among others.
What is chronic urticaria index? ›The Chronic Urticaria (CU) Index (IBT Labs; Lenexa, KS) is a commercially-available in vitro basophil histamine release assay in which patient serum is mixed with donor basophils and the released histamine levels are measured through a quantitative enzyme immunoassay.
How many people have chronic inducible urticaria? ›Chronic urticaria is reported to affect 1.8% of the population. The prevalence of chronic inducible urticaria is approximately 0.5% (15–25% of all cases of chronic urticaria).
How many people in the world have cholinergic urticaria? ›
| Type of urticaria | Prevalence, % |
|---|---|
| Cholinergic urticaria | 0.023 |
| Cold/heat urticaria | 0.019 |
| Angioedema | 0.028 |
| Chronic or recurrent urticaria | 0.385 |
ICD-10 code L50. 9 for Urticaria, unspecified is a medical classification as listed by WHO under the range - Diseases of the skin and subcutaneous tissue .